Optimal timing and duration of induction therapy for HIV-1 infection.

Marcel Curlin, Shyamala Iyer, John E. Mittler

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The tradeoff between the need to suppress drug-resistant viruses and the problem of treatment toxicity has led to the development of various drug-sparing HIV-1 treatment strategies. Here we use a stochastic simulation model for viral dynamics to investigate how the timing and duration of the induction phase of induction-maintenance therapies might be optimized. Our model suggests that under a variety of biologically plausible conditions, 6-10 mo of induction therapy are needed to achieve durable suppression and maximize the probability of eradicating viruses resistant to the maintenance regimen. For induction regimens of more limited duration, a delayed-induction or -intensification period initiated sometime after the start of maintenance therapy appears to be optimal. The optimal delay length depends on the fitness of resistant viruses and the rate at which target-cell populations recover after therapy is initiated. These observations have implications for both the timing and the kinds of drugs selected for induction-maintenance and therapy-intensification strategies.

Original languageEnglish (US)
JournalPLoS Computational Biology
Volume3
Issue number7
DOIs
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

human immunodeficiency virus
Human immunodeficiency virus 1
Viruses
Therapy
HIV Infections
Infection
HIV-1
Timing
Proof by induction
therapeutics
duration
Maintenance
virus
drug
infection
Virus
Drugs
drugs
viruses
Toxicity

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Ecology
  • Molecular Biology
  • Genetics
  • Ecology, Evolution, Behavior and Systematics
  • Modeling and Simulation
  • Computational Theory and Mathematics

Cite this

Optimal timing and duration of induction therapy for HIV-1 infection. / Curlin, Marcel; Iyer, Shyamala; Mittler, John E.

In: PLoS Computational Biology, Vol. 3, No. 7, 07.2007.

Research output: Contribution to journalArticle

@article{80c6b38db2814715984e5b25c9eabc79,
title = "Optimal timing and duration of induction therapy for HIV-1 infection.",
abstract = "The tradeoff between the need to suppress drug-resistant viruses and the problem of treatment toxicity has led to the development of various drug-sparing HIV-1 treatment strategies. Here we use a stochastic simulation model for viral dynamics to investigate how the timing and duration of the induction phase of induction-maintenance therapies might be optimized. Our model suggests that under a variety of biologically plausible conditions, 6-10 mo of induction therapy are needed to achieve durable suppression and maximize the probability of eradicating viruses resistant to the maintenance regimen. For induction regimens of more limited duration, a delayed-induction or -intensification period initiated sometime after the start of maintenance therapy appears to be optimal. The optimal delay length depends on the fitness of resistant viruses and the rate at which target-cell populations recover after therapy is initiated. These observations have implications for both the timing and the kinds of drugs selected for induction-maintenance and therapy-intensification strategies.",
author = "Marcel Curlin and Shyamala Iyer and Mittler, {John E.}",
year = "2007",
month = "7",
doi = "10.1371/journal.pcbi.0030133",
language = "English (US)",
volume = "3",
journal = "PLoS Computational Biology",
issn = "1553-734X",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Optimal timing and duration of induction therapy for HIV-1 infection.

AU - Curlin, Marcel

AU - Iyer, Shyamala

AU - Mittler, John E.

PY - 2007/7

Y1 - 2007/7

N2 - The tradeoff between the need to suppress drug-resistant viruses and the problem of treatment toxicity has led to the development of various drug-sparing HIV-1 treatment strategies. Here we use a stochastic simulation model for viral dynamics to investigate how the timing and duration of the induction phase of induction-maintenance therapies might be optimized. Our model suggests that under a variety of biologically plausible conditions, 6-10 mo of induction therapy are needed to achieve durable suppression and maximize the probability of eradicating viruses resistant to the maintenance regimen. For induction regimens of more limited duration, a delayed-induction or -intensification period initiated sometime after the start of maintenance therapy appears to be optimal. The optimal delay length depends on the fitness of resistant viruses and the rate at which target-cell populations recover after therapy is initiated. These observations have implications for both the timing and the kinds of drugs selected for induction-maintenance and therapy-intensification strategies.

AB - The tradeoff between the need to suppress drug-resistant viruses and the problem of treatment toxicity has led to the development of various drug-sparing HIV-1 treatment strategies. Here we use a stochastic simulation model for viral dynamics to investigate how the timing and duration of the induction phase of induction-maintenance therapies might be optimized. Our model suggests that under a variety of biologically plausible conditions, 6-10 mo of induction therapy are needed to achieve durable suppression and maximize the probability of eradicating viruses resistant to the maintenance regimen. For induction regimens of more limited duration, a delayed-induction or -intensification period initiated sometime after the start of maintenance therapy appears to be optimal. The optimal delay length depends on the fitness of resistant viruses and the rate at which target-cell populations recover after therapy is initiated. These observations have implications for both the timing and the kinds of drugs selected for induction-maintenance and therapy-intensification strategies.

UR - http://www.scopus.com/inward/record.url?scp=48049118407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049118407&partnerID=8YFLogxK

U2 - 10.1371/journal.pcbi.0030133

DO - 10.1371/journal.pcbi.0030133

M3 - Article

C2 - 17630827

AN - SCOPUS:34547567775

VL - 3

JO - PLoS Computational Biology

JF - PLoS Computational Biology

SN - 1553-734X

IS - 7

ER -